Recombinant factor VIIa: how safe is the stuff?
This editorial highlights the safety of rFVIIa in view of the relatively small number of thrombotic complications reported with the use of over 700,000 doses of rFVIIa. In many of the reported cases other predisposing factors for thrombosis were present. Nevertheless, the author agrees with the recommendation that until results of more clinical trials are reported, off-label use of rFVIIa should be limited for life-threatening bleeding complications.
– Maadh Aldouri